Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Digizyme is a digestive enzyme combination therapy primarily used to manage functional dyspepsia and other digestive insufficiencies. It typically contains fungal diastase, an amylolytic enzyme derived from *Aspergillus oryzae*, and pepsin, a proteolytic enzyme. Fungal diastase facilitates the breakdown of complex carbohydrates and starch into maltose, while pepsin aids in the digestion of proteins by cleaving them into smaller peptides. This dual action helps alleviate symptoms of indigestion, such as bloating, flatulence, and abdominal discomfort, by supplementing the body's endogenous digestive capacity. It is widely available in syrup and tablet formulations for oral administration and is frequently utilized in cases of pancreatic insufficiency or general digestive distress following heavy meals.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Digizyme.